SEC Filing Summary: Tharimmune, Inc. (THAR)
Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. on May 22, 2024. The registrant is a Delaware corporation with its principal executive offices in Bridgewater, NJ. The filing reports a corporate action regarding the company's capital structure effective in late May 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance results.
Material Changes
- Reverse Stock Split: The Company filed a Certificate of Amendment to effect a 1-for-15 reverse stock split of its issued and outstanding common stock.
- Effective Date: The split becomes effective at 4:01 p.m. Eastern time on May 24, 2024.
- Trading Resumption: Commencing with the opening of trading on May 28, 2024, the common stock will trade on a post-split basis on The Nasdaq Capital Market under the existing symbol "THAR."
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the execution of the reverse split. The primary purpose of the filing is to disclose the amendment to the Certificate of Incorporation and the associated press release.
Investor Verification Checklist
- Verify the 1-for-15 reverse split ratio and its impact on share count and price per share.
- Confirm the effective time of the split (May 24, 2024, at 4:01 p.m. ET) and the resumption of trading (May 28, 2024).
- Review the attached Certificate of Amendment (Exhibit 3.1) for any additional terms regarding fractional shares or rounding.
- Check the press release (Exhibit 99.1) for the Company's stated rationale for the reverse split.